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Specific antibodies against infections most relevant to patients with primary immunod-
eficiency diseases are not routinely evaluated in commercial polyclonal immunoglobulin
preparations. A polyclonal immunoglobulin prepared from plasma of donors having high
neutralizing antibody titers to respiratory syncytial virus (RSV) was studied for the presence
of antibody titers against seven additional respiratory viruses. While donors were not
selected for antibody titers other than against RSV, the immunoglobulin preparation had
significantly higher titers to 6 of 7 viruses compared to those present in 10 commercially
available therapeutic immunoglobulin products (p0.01 to p0.001). To consider this
as a donor-specific attribute, 20 random donor plasma samples were studied individually
and identified a significant correlation between the RSV antibody titer and other respiratory
virus titers: donors with high RSV titers were more likely to have higher titers to other
respiratory viruses. These findings suggest either some humoral antiviral response bias
or more frequent viral exposure of certain individuals.
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Introduction
The majority of primary immunodeficiency diseases (PIDD) include deficiencies of immunoglobu-
lin quantity and/or quality (1, 2). Left untreated, these deficiencies lead to increased risk for recurrent
upper and lower respiratory tract infections as well as for bacterial sepsis (3). While bacterial sepsis
can result in immediate fatality, recurrent respiratory infections can result in chronic lung disease
and bronchiectasis (4). Fortunately, the infectious susceptibilities in PIDD along with its risks can
be mitigated to a substantive degree by immunoglobulin replacement therapy (5, 6). Therapeutic
immunoglobulin is able to reduce incidence of infection in PIDD in large part owing to the diverse
antibody specificities against pathogens contained within plasma of thousands of different healthy
donors.
The quality of therapeutic immunoglobulin is monitored and evaluated in a number of ways.
Intact antigen recognition by IgG in therapeutic immunoglobulin products is gaged by the presence
of minimal titers of specific antibodies expected in the general population in what is referred to
as potency tests. In the United States, the Food and Drug Administration requires potency tests
to achieve minimal standards for Measles, Diphtheria, and Polio (FDA CFR 640.104). While these
pathogens remain relevant at least to some degree – especially Measles – they are not infectious
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diseases specifically relevant to PIDD patients needing
immunoglobulin replacement. Commercially available
immunoglobulins are therefore not standardized for specific
antibody content for the most common infectious diseases to
which PIDD patients are susceptible. Studies of these titers
in available products have reported wide variation (7). How
much specific antibody within a given dose of a therapeutic
immunoglobulin preparation is needed to provide optimal
resistance for PIDD patients remains an open question. One
thing that is clear, however, is that increasing doses of standard
polyclonal immunoglobulin are associated with decreasing
incidence of infection in PIDD patients (8, 9).
Respiratory syncytial virus (RSV) is a relatively ubiquitous
virus, but causes infections with severe morbidity and a resul-
tant high mortality in PIDD and otherwise immunodeficient
patients (10). In the present work, an investigational intravenous
immunoglobulin (IVIG) product (RI-002) obtained from donors
with high-titer antibodies against RSV was compared to com-
mercially available polyclonal therapeutic IVIG products. RI-002
IVIG was used in a recently completed Phase III clinical trial in
PIDD patients as standard replacement therapy (data currently
under review). While not specifically intended for RSV activity in
that trial, RI-002 prevented and treated experimental infection as
well as restored pulmonary histology in normal and immune com-
promised cotton rats given RSV by nasal challenge (manuscript in
preparation).
Since RI-002 was generated from donors with a high antibody
response to RSV, we questioned whether this might reflect their
being high responders to not only RSV but also other viruses. In
other words, might they represent either an extreme in humoral
antiviral responders or a selection of individuals highly exposed to
respiratory viruses. To this end, we evaluated the antibody titers in
RI-002 to several common respiratory viruses and compared them
to those in other 10 commercially available IVIG preparations,
which were not derived from donors with high titers against
respiratory viruses.
Materials and Methods
Intravenous Immunoglobulin
Investigational IVIG (RI-002; kindly provided by ADMA Bio-
logics) was manufactured using Cohn–Oncley Fractionation to
FDA published specifications for intravenous immune globulin
and included plasma from donors with high-levels of RSV anti-
bodies. A donor with high titers to RSV was determined by RSV
neutralization assay testing (MNA). IVIG was tested and released
to meet the FDA guidance for the treatment of PIDD patients
requiring that the donor pool consist of at least 1,000 donors and
meet minimum titers for measles, polio, tetanus, and Hepatits
B. Thus, RI-002 (ADMA Biologics Inc.) was manufactured to
achieve standardized levels of anti-RSV potency as well as meet all
standards required for a commercially available polyclonal IVIG.
Of note that latter characteristic was not a feature of the previously
available polyclonal RSV hyperimmune immunoglobulin. RI-002
therefore met standards for Measles, Polio, and Diphtheria titers
(which are set at 0.60 CBER Reference, 0.28 CBER Reference,
and 1.21U/ml, respectively) with values of 0.73–2.70 CBER
Reference, 0.83–1.24 CBER Reference, and 8.00–11.25U/ml,
respectively.
IVIG Utilized for Titer Testing
Three different batches of investigational IVIG (RI-002) produced
at 3 separate times from different donor plasma pools and 10
different lots of commercially available IVIG (7 different man-
ufactures/brands) were evaluated by ELISA to quantitate titers
to [influenza A and B, RSV, parainfluenza virus serotypes 1, 2,
and 3 (PIV 1-3), human metapneumovirus (hMPV), and coron-
avirus 229E (CoV 229E) and coronavirus OC43 (CoV OC43)] as
described below. The ELISA assay was run on three separate dates
in a blinded manner.
Individual Donor Sample Collection and
Purification by Protein-A Chromatography
Plasma samples from 20 random donors were collected through
a commercial plasma collection center and all donors provided
their written consent for pathogen titer testing. All plasma and
donor samples were collected in US FDA approved collection
centers using approved standard operating procedures and testing
methods, and all donors were compensated for their donation
in accordance with FDA polices. Each donor consented to have
their plasma used for various purposes including but not lim-
ited to commercial manufacturing, additional laboratory testing,
reagents, etc. Plasma was purified by protein-A chromatography
into their Ig fractions. Bulk recombinant Protein-A Sepharose FF
resin was washed and packed in 15ml conical and diluted with
an equal volume of buffer and centrifuged at 2500 rpm for 5min.
Supernatants were removed for Protein-A chromatography and
the pellets discarded. Sample supernatants were transferred to
Protein-A columns corresponding to sample identification num-
ber. Flow through of approximately 6ml was collected by gravity
flow. Two CV (4ml) of equilibration buffer were passed through
the columns, combined with the flow through volume and stored
at 4°C. Bound material from each column was removed with 5ml
of elution buffer (0.1M citrate, pH 3.4) and collected in 15ml
conical tubes containing 400μl of 3MTris base to bring the eluates
to pH 7.8. The columns were centrifuged as described above to
collect the entire elution buffer. Final volume for each elution was
6.0ml. Recovery of Ig was calculated based upon absorbance at
280 nm/1.4 of 1:5 dilutions of sample aliquots.
The purified Ig fraction was run three separate times for deter-
mination of antibody levels using an ELISA as for the IVIG prepa-
rations. Antibody titers to each of the nine respiratory viruseswere
obtained from each run repeated on three separate occasions; and
the results transformed to log2 scale.
Viral Titer IgG ELISA
ELISA was performed to detect virus-specific IgG for nine res-
piratory viruses [influenza A and B, RSV, parainfluenza virus
serotypes 1, 2, and 3 (PIV 1-3), hMPV, and coronavirus 229E
(CoV 229E) and coronavirus OC43 (CoV OC43)] according to
published methods (11). Viral antigen preparations were cre-
ated from infected whole-cell lysates for all viruses as described.
Briefly, influenza viruses were grown in MDCK cells, RSV was
grown Hep-2 cells, PIV 1–3 viruses were grown in Vero cells,
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FIGURE 1 | Box plots showing 3 RI-002 lots and 10 commercial lots
distribution of titers to respiratory syncytial virus (A) and titers to
respiratory viruses influenza A (B), influenza B (C), parainfluenza virus
serotypes 1 (D), parainfluenza virus serotypes 2 (E), parainfluenza virus
serotypes 3 (F), human metapneumovirus (G), coronavirus 229E (H), and
coronavirus OC43 (I).
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hMPVwas grown in LLC-MK2 cells, coronavirus 229Ewas grown
in MRC-5 cells, and coronavirus OC43 was grown in HRT-18G
cells. After cytopathic effect was extensive, the cells were scraped
into the supernatant and centrifuged at low speed. The pellets were
resuspended into distilled sterile water/0.5%NP40, sonicated, and
then clarified. CoV 229E and hMPV were further purified on
a 20%/60% discontinuous sucrose gradients using ultracentrifu-
gation and bands were diluted in Tris NaCl EDTA buffer. Viral
antigen preparations were stored at 80°C until use.
ELISA testing of IVIG was performed by an investigator
blinded to the type of product being tested. A total of 13 IVIG
products were procured and labeled A through M. All products
were diluted with dilution buffer (PBS with 0.3% Tween 20 and
0.1 M EDTA) to a standard concentration of 50mg of IgG/ml.
Each viral antigen preparation was diluted to a previously deter-
mined concentration in bicarbonate buffer and coated separately
on ELISA plates and stored overnight in humidified chambers
at 4°C. The following day, plates were washed and eight serial
twofold dilutions in duplicate of unknown IVIG product were
incubated on the antigen-coated plates at room temperature in
humidified chambers for 3 h (initial IVIG dilution utilized was
1:1600). Plates were then washed and bound IgG was detected
with alkaline phosphatase-conjugated goat anti-human IgG fol-
lowed by substrate. A known serum standard was included on
each plate and the IgG titer for a specific virus was defined as the
highest dilution with an optical density (OD) of 0.20.
Statistical Analysis
Titers data were tabulated with descriptive statistics, and the dif-
ference between the RI-002 and commercial IVIG preparations
was presented as the ratio of geometric means (RGM) along with
95% Confidence intervals for the RGM. p values for testing the
null hypothesis that the RGM equaled 1 were determined via
a two-sample two-tailed Student’s t-test (significance defined as
p< 0.05).
To evaluate the correlation between the titers to RSV and the
titers to another non-RSV respiratory virus at the donor level,
antibody data were paired by matching the donor ID within the
same ELISA Assay replicate (three separate repeats referenced as
Run 1, 2, and 3). Titers to RSV from a donor were paired with the
titers to another non-RSV virus of the same donor. Hence, a total
of 20 pairs were created within a Run and a total of 60 pairs were
created within a comparison owing to the replicates.
Linear correlation was assessed between the titers to RSV and
the titers to another non-RSV virus using Pearson correlation
coefficient on both linear and on log2 scale. All analysis was
performed using SAS version 9.3.
Results and Discussion
To evaluate the hypothesis that therapeutic polyclonal
immunoglobulin prepared from donor plasma with high
titers of anti-RSV IgG may also have evidence of increased
humoral immunity against other viral pathogens, RI-002 was
compared in aggregate to 10 different lots of commercially
available standard polyclonal IVIG products. In each case, the
specific IgG against RSV antigens was evaluated by ELISA as
well as the specific IgG against antigens prepared from eight
TABLE 1 | Titers to respiratory viruses: comparisons between RI-002 and
commercial IVIG batches.
Virus Ratio of geometric means
(95% CI) (RI-002/commercial IVIG)a
p Valueb
RSV 1.861 (1.249, 2.771) 0.003
PIV 1 1.792 (1.282, 2.505) 0.001
OC43 1.610 (1.127, 2.301) 0.010
PIV 2 1.601 (1.160, 2.210) 0.005
229E 1.494 (1.144, 1.950) 0.004
Flu A 1.402 (1.067, 1.843) 0.016
Flu B 1.316 (1.026, 1.688) 0.031
hMPV 1.264 (0.990, 1.613) 0.060
PIV 1 and 2 1.694 (1.250, 2.296) 0.001
OC43 and 229 E 1.551 (1.237, 1.945) <0.001
All virusesc 1.529 (1.227, 1.907) <0.001
aThree randomly selected RI-002 batches and seven unselected commercial lots of IVIG
from four different manufactures/brands.
bTwo-group t-test for null hypothesis of no difference between the groups in geometric
means (i.e., ratio of geometric means=1).
cPooled RSV, respiratory syncytial virus; Flu A, influenza A; Flu B, influenza B; hMPV,
humanmetapneumovirus; PIV 1, parainfluenza virus serotypes 1; PIV 2, parainfluenza virus
serotypes 2; OC43, coronavirus CoV OC43; 229E, coronaviruses CoV229E.
other respiratory viruses. These included influenza A and B,
hMPV, parainfluenza virus 1, 2, and 3, coronavirus OC42, and
V299E. In each case, the mean ratio of the geometric mean of the
titer of RI-002 to the commercial polyclonal IVIG preparations
was higher in RI-002 (Figure 1). The difference in these means
achieved statistical significance for all but one of the viruses
(hMPV, which demonstrated a trend toward significance). In
aggregate, the mean titers were 1.5-fold higher in RI-002 and
ranged from 1.4 to 1.7-fold higher depending upon the particular
virus (Table 1). Not surprisingly, RSV was the highest. While
other lots of IVIG showed a wide range of titers to the other
viruses and often had a high titer to one virus but low titer to other
viruses, RI-002 was consistent from lot to lot and demonstrated
consistently high titers to all of the viruses. Importantly, since
RI-002 is standardized to high RSV titers, the repeated findings
of high titers to these other viruses across the lots tested here is
likely to be a consistent feature across all lots prepared in the
same manner.
While the specific levels of anti-pathogen antibodies required in
IVIG to provide protection from the many pathogens that infect
patients with PIDD is unknown, it stands to reason that a greater
quantity of antibody to a specific pathogen will provide a greater
level of protection (12). A number of variables also need to be
factored into that equation, such as the actual quality (affinity and
avidity) of the antigen-specific antibody as well as the inflection
point past, which increasing titers become irrelevant to protection.
Further study of exogenously applied immunoglobulin is required
to gain the insights into both questions in a way that will translate
into clinical efficacy. There is, however, evidence to suggest that
having high pathogen-specific antibody in IVIG may translate
into improved clinical outcomes with regards to that particular
pathogen as was demonstrated for Streptococcus pneumonia and
otitis (13).
The results, however, demonstrate that IVIG manufactured
from a plasma pool derived from high titer anti-RSV plasma
donors contains high titers of antibodies to other respiratory
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G
H
FIGURE 2 | Correlation between titers to respiratory syncytial virus (RSV) and titers to respiratory viruses influenza A (A) and influenza B (B),
parainfluenza virus serotype 1 (C), parainfluenza virus serotype 2 (D), parainfluenza virus serotype 3 (E), human metapneumovirus (F), coronavirus
229E (G), and coronavirus OC43 (H).
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TABLE 2 | Linear correlation coefficient between titers to RSV and titers to
non-RSV virus.
Scale Pearson linear correlation coefficients of titers to
RSV and titers to other respiratory viruses
Flu A Flu B hMPV PIV1 PIV2 PIV3 OC43 229E
Log2 0.49a 0.54a 0.35b 0.56a 0.41b 0.67a 0.29c 0.41a
Linear 0.49a 0.59a 0.28c 0.50a 0.24d 0.59a 0.34b 0.40b
ap0.001.
bp0.01.
cp0.05.
dp>0.05.
viruses and suggests that theremay be a direct correlation between
antibody responder status of donors to RSV and their respon-
der status to other viruses. To evaluate this, we prepared an
immunoglobulin fraction from 20 randomly selected plasma
donors containing high, medium, and low titers to RSV and
measured their antibody levels to the other 9 respiratory virus
antigens. A direct correlation was present between the RSV titers
and those to all nine of the other respiratory viruses (Figure 2).
Thus, the higher the RSV titer values, the greater the titers to other
non-RSV respiratory viruses. Likewise, lower titers to RSV corre-
latedwith lower titers to the other respiratory viruses. In each case,
correlation coefficients were statistically significant (p< 0.05) and
ranged from 0.29 to 0.67 log2 scale (Figure 2; Table 2).
The exact reason that RI-002 contains elevated antibody titers
to other respiratory viruses is not entirely clear as is the reason for
the positive correlation betweenRSV titer and that to other viruses
in the immunoglobulin from individual donors tested. There are,
however, a number of possibilities to consider. First, it is possible
that certain individuals are high humoral immune responders
either in general or specifically against intracellular antigens.
Given the diversity inMHCand the concomitant linkages ofMHC
alleles to immunity in general, this is at least plausible. Specifically,
individuals having particular MHC alleles have higher humoral
response after viral vaccination (14, 15). Thus, the donors who
were selected based on their high responses to RSV may also
have been high responders to other respiratory viruses. Whether
these donorsmay also be high responders to pathogens other than
respiratory viruses remains to be studied. Another possibility to
account for the higher response of high-titer antibody RSVdonors
to other non-RSV respiratory viruses is that these donors may
have experience to a greater diversity of viral infections. This could
be a feature of their occupation or other demographic considera-
tions that are not routinely considered in selecting plasma donors
for the manufacture of therapeutic immunoglobulin. Given the
diversity of high antiviral titers in both the IVIG preparation and
the individual donors, we would hypothesize the former. Formal
testing of elite antiviral humoral response, however, needs further
study to establish this hypothesis. Moreover, whether these find-
ings regarding the composition of a hyperimmune IVIG translate
into clinical efficacy for protection against a diversity of infections,
however, remains to be determined.
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